PMID- 37357300
OWN - NLM
STAT- MEDLINE
DCOM- 20230627
LR  - 20230628
IS  - 2426-0266 (Electronic)
IS  - 2274-5807 (Linking)
VI  - 10
IP  - 3
DP  - 2023
TI  - Neuroprotective Effects of IVIG against Alzheimer' s Disease via Regulation of 
      Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice.
PG  - 581-594
LID - 10.14283/jpad.2023.56 [doi]
AB  - BACKGROUND: The results of clinical trials for Alzheimer's disease (AD) patients 
      treated with Intravenous immunoglobulin (IVIG) revealed inconsistency in 
      efficacy. OBJECTIVE: To explore the neuroprotective effects and possible 
      mechanisms of different IVIG in 3xTg-AD mice. METHODS: 3-month-old 3xTg-AD mice 
      were administered intraperitoneally with different IVIG (A/B/C) for 3 months and 
      then the therapeutic effects were observed and tested at 9 months of age. The 
      bioavailability of IVIG and Abeta40/42 concentrations in parietotemporal cortex was 
      measured by ELISA. Behavioral tests were performed to examine cognitive 
      functions. Immunohistochemistry was utilized to examine the deposition of Abeta, the 
      phosphorylation of tau, the levels of GFAP and Iba-1 in the hippocampus. 
      Proteomics, Luminex assay and parallel reaction monitoring were performed to 
      identify and verify the proteins that showed a marked change in the hippocampus. 
      RESULTS: IVIG-C was more effective than IVIG-A and IVIG-B in counteracting 
      cognitive deficits, ameliorating Abeta deposits and tau phosphorylation, attenuating 
      the activation of microglia and astrocytes in the hippocampus and inhibiting the 
      secretion of pro-inflammatory factors. IVIG-C affected innate immunity and 
      suppressed the activation of antigen processing and presentation by MHC class I 
      molecule (APP-MHC-I). CONCLUSION: The efficacy of different IVIG on AD was 
      significantly different, and only IVIG-C has been confirmed to possess 
      significant neuroprotective effects, which are related to the inhibition of 
      APP-MHC-I. IVIG may be a potential therapeutic for AD but further research is 
      needed to evaluate the functional of IVIG before clinical trials of AD treatment.
FAU - Fei, Z
AU  - Fei Z
AD  - Xi Du and Haijun Cao , Institute of Blood Transfusion, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, Chengdu 610052, China, 
      shela44@163.com; chjr007@163.com. Tel: 86-28-61648527.
FAU - Pan, B
AU  - Pan B
FAU - Pei, R
AU  - Pei R
FAU - Ye, S
AU  - Ye S
FAU - Wang, Z
AU  - Wang Z
FAU - Ma, L
AU  - Ma L
FAU - Zhang, R
AU  - Zhang R
FAU - Li, C
AU  - Li C
FAU - Du, X
AU  - Du X
FAU - Cao, H
AU  - Cao H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - J Prev Alzheimers Dis
JT  - The journal of prevention of Alzheimer's disease
JID - 101638820
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (tau Proteins)
SB  - IM
MH  - Mice
MH  - Humans
MH  - Animals
MH  - *Alzheimer Disease
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - *Neuroprotective Agents/pharmacology/therapeutic use
MH  - Histocompatibility Antigens Class I/therapeutic use
MH  - Antigen Presentation
MH  - tau Proteins/metabolism
MH  - Mice, Transgenic
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - MHC-I
OT  - antigen processing and presentation
OT  - intravenous immunoglobulin
OT  - neuroinflammation
COIS- The authors declare that they have no competing interests.
EDAT- 2023/06/26 00:41
MHDA- 2023/06/27 06:42
CRDT- 2023/06/25 23:13
PHST- 2023/06/27 06:42 [medline]
PHST- 2023/06/26 00:41 [pubmed]
PHST- 2023/06/25 23:13 [entrez]
AID - 10.14283/jpad.2023.56 [doi]
PST - ppublish
SO  - J Prev Alzheimers Dis. 2023;10(3):581-594. doi: 10.14283/jpad.2023.56.